

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

SW1990

RRID:CVCL_1723

Type: Cell Line

Proper Citation

RRID:CVCL_1723

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1723

Proper Citation: RRID:CVCL_1723

Description: Cell line SW1990 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:6871872](#), [PMID:12068308](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:17217822](#), [PMID:18380791](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21054984](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27067801](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31452783](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW1990

Synonyms: SW-1990, SW 1990

Cross References: BTO:BTO_0003491, CLO:CLO_0009192, CLO:CLO_0009194, EFO:EFO_0002365, CLDB:cl4438, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ATCC:CRL-2172, BioGRID_ORCS_Cell_line:1029, BioSample:SAMN03472179, BioSample:SAMN10987630, cancercellines:CVCL_1723, CCRID:1101HUM-PUMC000472, CCRID:3101HUMTCHu201, CCRID:4201HUM-CCTCC00246, CCTCC:GDC0246, Cell_Model_Passport:SIDM01165, CGH-DB:184-1, CGH-DB:9275-4, ChEMBL-Cells:ChEMBL3308789, ChEMBL-Targets:ChEMBL1075592, CLS:305068, Cosmic:724871, Cosmic:910907, Cosmic:913312, Cosmic:1609543, Cosmic:2434093, Cosmic-CLP:910907, DepMap:ACH-000155, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910907, GEO:GSE79953, GEO:GSM206550, GEO:GSM621893, GEO:GSM784708, GEO:GSM887672, GEO:GSM888764, GEO:GSM1024415, GEO:GSM1670506, IARC_TP53:27582, IGRhCellID:SW1990, KCB:KCB_2012113YJ, LiGeA:CCLE_709, LINCS_LDP:LCL-1750, MetaboLights:MTBLS9288, Pharmacodb:SW1990_1536_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1723, PubChem_Cell_line:CVCL_1723, TOKU-E:3217, Ubigen:YC-C124, Wikidata:Q54971096

ID: CVCL_1723

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260905T182522+0000

Ratings and Alerts

No rating or validation information has been found for SW1990.

No alerts have been found for SW1990.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 420 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Zhang S, et al. (2026) Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Cell reports. Medicine, 7(3), 102660.

Szigeti KA, et al. (2026) Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma. Scientific reports, 16(1), 4144.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(13), 3194.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Lin Q, et al. (2026) Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2279.

Wang F, et al. (2026) Lactate Facilitates the Survival and Invasion of Pancreatic Cancer Cells Under Glucose Deprivation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(7), e71726.

Deng X, et al. (2026) RBM15-Mediated m6A Modification Regulates Proliferation and Migration of Pancreatic Cancer Cells via the lncRNA LINC01320/miR-1287-5p/FBXO11 Axis. *Biomolecules & therapeutics*, 34(3), 618.

Bevilacqua R, et al. (2026) Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies. *NPJ precision oncology*, 10(1).

Krishna Kumar N, et al. (2026) SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. *Cell reports*, 45(6), 117387.

Tang R, et al. (2026) Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. *Cancer cell*.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Zhu L, et al. (2026) The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. *Drug design, development and therapy*, 20, 568551.

Qin G, et al. (2026) HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1 transcriptional activation in pancreatic cancer. *Molecular cell*, 86(14), 2794.

Bai Y, et al. (2026) USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibiting glucose uptake. *Cancer letters*, 642, 218299.

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing

apoptosis induction. bioRxiv : the preprint server for biology.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell reports. Medicine, 7(4), 102688.